18299-15-5

Basic information

• Product Name: 4-HYDROXY-3-METHYLBENZYL ALCOHOL
• Synonyms: 4-HYDROXY-3-METHYLBENZYL ALCOHOL;RARECHEM AL BD 0693;4-(HydroxyMethyl)-2-Methylphenol
• CAS NO: 18299-15-5
• Molecular Formula: C₈H₁₀O₂
• Molecular Weight: 138.16
• Product Categories: Benzhydrols, Benzyl & Special Alcohols
• Mol File: 18299-15-5.mol
• Article Data: 2

Chemical Properties

• Melting Point: 81-84 °C
• Boiling Point: 288.8±25.0 °C(Predicted)
• Appearance: /
• Density: 1.171±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 10.09±0.18(Predicted)
• CAS DataBase Reference: 4-HYDROXY-3-METHYLBENZYL ALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-3-METHYLBENZYL ALCOHOL(18299-15-5)
• EPA Substance Registry System: 4-HYDROXY-3-METHYLBENZYL ALCOHOL(18299-15-5)

Safety Data

• Hazardous Substances Data: 18299-15-5(Hazardous Substances Data)

Usage

General Description

4-Hydroxy-3-methylbenzyl alcohol is a chemical compound with the molecular formula C8H10O2. It is also known as p-cresol and is commonly found in natural sources such as coal tar and certain essential oils. It is used in the manufacturing of various products such as perfumes, disinfectants, and pharmaceuticals. It has antibacterial properties and is often used as an antiseptic and preservative in cosmetic and personal care products. Additionally, p-cresol has been studied for its potential use in the treatment of certain neurological disorders. However,

Upstream product

• 15174-69-3 4-hydroxy-3-methyl-benzaldehyde 
• 56-23-5 tetrachloromethane 
• 50-00-0 formaldehyd 
• 7732-18-5 water 
• 95-48-7 ortho-cresol 

Downstream Products

• 637352-50-2 ethyl [4-(hydroxymethyl)-2-methylphenoxy]acetate 
• 637352-69-3 ethyl [4-({butyl[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)-2-methylphenoxy]acetate 
• 637352-61-5 ethyl [4-({(2-cyclopropylethyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)-2-methylphenoxy]acetate 
• 637352-70-6 ethyl [4-({(2-methoxyethyl)[2-methyl-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)-2-methylphenoxy]acetate 
• 637352-60-4 ethyl [2-methyl-4-({pentyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)phenoxy]acetate 
• 637352-58-0 ethyl [4-({butyl[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)-2-methylphenoxy]acetate 
• 637353-08-3 ethyl (4-{[butyl(2,4'-dimethyl-1,1'-biphenyl-3-yl)amino]methyl}-2-methylphenoxy)acetate 
• 637352-64-8 methyl [2-methyl-4-({[2-(methylthio)ethyl][4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)phenoxy]acetate 
• 637352-94-4 ethyl (4-{[(3-bromo-2-methylphenyl)(butyl)amino]methyl}-2-methylphenoxy)acetate 
• 637352-51-3 ethyl [4-(bromomethyl)-2-methylphenoxy]acetate 
• 439134-88-0 ethyl [4-(chloromethyl)-2-methylphenoxy]acetate 

Relevant articles and documents

Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents

Non-alcoholic fatty liver disease (NAFLD) has become the most common hepatic disease, while no drug was approved until now. The previous study reported that the quadruple FFA1/PPAR-α/γ/δ agonist RLA8 provided better efficacy than obeticholic acid on NASH. In the present study, two design strategies were introduced to explore better quadruple FFA1/PPAR-α/γ/δ agonists with improved metabolic stability. These efforts ultimately resulted in the identification of ZLY18, a quadruple FFA1/PPAR-α/γ/δ agonist with twice higher metabolic half-life than RLA8 in the liver microsome. In the triton-1339W-induced hyperlipidemic model, ZLY18 reversed hyperlipidemia to an almost normal level, which exhibited far stronger lipid-lowering effects than that of RLA8. Moreover, ZLY18 significantly decreased steatosis, hepatocellular ballooning, inflammation and liver fibrosis in NASH model even better than RLA8. Further mechanism studies suggested that ZLY18 exerts stronger effects than RLA8 on the regulation of the gene related to lipid synthesis, oxidative stress, inflammation and fibrosis. In addition, ZLY18 is more effective than pirfenidone in the prevention of CCl4-induced liver fibrosis. Besides, ZLY18 has an acceptable safety profile in the acute toxicity study at a high dose of 500 mg/kg. Therefore, ZLY18 represents a novel and highly promising quadruple FFA1/PPAR-α/γ/δ agonist worth of further investigation and development.